<DOC>
	<DOCNO>NCT00009802</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Calcitriol may increase effectiveness paclitaxel make tumor cell sensitive drug . PURPOSE : Phase I trial study effectiveness combine calcitriol paclitaxel treat patient advance solid tumor .</brief_summary>
	<brief_title>Calcitriol Plus Paclitaxel Treating Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : - Determine toxic effect maximum tolerate dose calcitriol combine paclitaxel patient advance solid tumor . - Determine effect administration calcitriol pharmacokinetics paclitaxel patient . - Determine effect administration paclitaxel pharmacokinetics calcitriol patient . OUTLINE : This dose-escalation study calcitriol . During course 1 , patient receive oral calcitriol daily day 1-3 week 1-6 paclitaxel IV 1 hour day 1 week 1 day 3 week 2-6 . During course 2 subsequent course , patient receive oral calcitriol daily day 1-3 paclitaxel IV 1 hour day 3 week 1-6 . Treatment continue every 8 week absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos calcitriol maximum tolerate dose ( MTD ) determine . The MTD define high dose give estimate probability dose-limiting toxicity 0.30 . PROJECTED ACCRUAL : A total 60 patient accrue study .</detailed_description>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Calcitriol</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven advanced cancer curable standard therapy Brain metastasis allow follow definitive radiotherapy PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic : Bilirubin great 1.5 mg/dL SGOT great 4 time normal Renal : Creatinine great 2.0 mg/dL Calcium great 10.5 mg/dL Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective doublebarrier contraception least 1 week , , least 2 week study No active infection serious concurrent condition No symptomatic peripheral neuropathy great grade 1 PRIOR CONCURRENT THERAPY : Biologic therapy : At least 3 week since prior regional systemic biologic therapy Chemotherapy : At least 3 week since prior chemotherapy ( 6 week mitomycin nitrosourea ) Endocrine therapy : Not specify Radiotherapy : See Disease Characteristics At least 3 week since prior radiotherapy Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>